VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
Public ClinicalTrials.gov record NCT00561925. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® in Antiretroviral Therapy naïve HIV-1 Infected Patients (VERxVE)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients after 48 weeks of treatment. Secondary objectives are to evaluate safety and pharmacokinetics of NVP XR and NVP IR.
Study identification
- NCT ID
- NCT00561925
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,068 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2007 (Type not available)
- Primary completion
- Nov 2011 (Actual)
- Completion
- Not listed
- Last update posted
- Apr 7, 2014
Started 2007
United States locations
- U.S. sites
- 41
- U.S. states
- 15
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1100.1486.0040 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1100.1486.0013 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1100.1486.0017 Boehringer Ingelheim Investigational Site | Bakersfield | California | — | — |
| 1100.1486.0001 Boehringer Ingelheim Investigational Site | Beverly Hills | California | — | — |
| 1100.1486.0057 Boehringer Ingelheim Investigational Site | Beverly Hills | California | — | — |
| 1100.1486.0059 Boehringer Ingelheim Investigational Site | Beverly Hills | California | — | — |
| 1100.1486.0035 Boehringer Ingelheim Investigational Site | Long Beach | California | — | — |
| 1100.1486.0025 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1100.1486.0034 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1100.1486.0041 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1100.1486.0032 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 1100.1486.0028 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 1100.1486.0023 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 1100.1486.0029 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 1100.1486.0048 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 1100.1486.0037 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1100.1486.0043 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1100.1486.0012 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1100.1486.0007 Boehringer Ingelheim Investigational Site | Miami Beach | Florida | — | — |
| 1100.1486.0039 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1100.1486.0050 Boehringer Ingelheim Investigational Site | Vero Beach | Florida | — | — |
| 1100.1486.0014 Boehringer Ingelheim Investigational Site | Wilton Manors | Florida | — | — |
| 1100.1486.0031 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | — | — |
| 1100.1486.0010 Boehringer Ingelheim Investigational Site | Macon | Georgia | — | — |
| 1100.1486.0053 Boehringer Ingelheim Investigational Site | Boise | Idaho | — | — |
| 1100.1486.0002 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1100.1486.0026 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1100.1486.0020 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | — | — |
| 1100.1486.0019 Boehringer Ingelheim Investigational Site | Berkley | Michigan | — | — |
| 1100.1486.0006 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 1100.1486.0027 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1100.1486.0055 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | — | — |
| 1100.1486.0003 Boehringer Ingelheim Investigational Site | Huntersville | North Carolina | — | — |
| 1100.1486.0005 Boehringer Ingelheim Investigational Site | Akron | Ohio | — | — |
| 1100.1486.0004 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1100.1486.0018 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1100.1486.0038 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1100.1486.0044 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 1100.1486.0054 Boehringer Ingelheim Investigational Site | Harlingen | Texas | — | — |
| 1100.1486.0009 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1100.1486.0046 Boehringer Ingelheim Investigational Site | Annandale | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 161 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00561925, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 7, 2014 · Synced Nov 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00561925 live on ClinicalTrials.gov.